NanoBio's NB-001 meets Phase II endpoints

NanoBio (Ann Arbor, Mich.) said NB-001 met the primary endpoint of time to healing in a Phase II trial in 332 patients with herpes labialis. The company said the double-blind, vehicle-controlled U.S. ...